

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

CLARIFICATION ANNOUNCEMENT

This announcement is made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) with respect to a second report recently issued by Flaming Research (“**Flaming**”) (the “**Second Report**”) which contains allegations against the Company, and is published by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcement of the Company dated 28 September 2018 in relation to the Report and the Company’s refutation and/or clarification of the allegations made in the Report (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Company denies all of the allegations against the Group in the Second Report. The Second Report comprises statements which are misleading, biased, selective, inaccurate and incomplete as well as groundless allegations and irresponsible speculations. The management of the Company reiterated that it has no record of being contacted by Flaming before and after the Report or the Second Report was published.

The Company hereby solemnly reminded Flaming and the relevant persons who orchestrated the publication of the Report and the Second Report to seriously consider that the Company has taken necessary legal actions with respect to the Report and the Second Report. If the publication of misleading, biased, selective, inaccurate and incomplete as well as groundless allegations and irresponsible speculations continues with the attempt to damage the Company's corporate image, credit and reputation, cause significant fluctuation in the share price of the Company, and disrupt the securities trading market, the Company will take all necessary legal actions until Flaming and the relevant persons in relation to the matters set out in the Report and the Second Report are subject to fair and reasonable judgment by the law and the market.

The management and scientists of the Company hereby invite qualified research institutes with disclosed identity to engage in open and public discussion, but firmly oppose the conduct of Flaming with undisclosed identity under the disguise of a research institute to damage the Company's reputation. The Company is committed to undertake all necessary legal actions to protect the legal interests of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 3 October 2018

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.

* *For identification purposes only*